

Public Assessment Report

Scientific discussion

Atropin Abboxia (atropine sulfate)

SE/H/2460/01-02/MR

This module reflects the scientific discussion for the approval of Atropin Abboxia. The procedure was finalised on 2022-02-04. For information on changes after this date please refer to the module 'Update'.

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, a marketing authorisation has been granted for Atropin Abboxia, 0,5 mg/ml, 1 mg/ml, Solution for injection.

The active substance is atropine sulfate. A comprehensive description of the indication and posology is given in the SmPC.

For recommendations to the marketing authorisation not falling under Article 21a/22a/22 of Directive 2001/83/EC and conditions to the marketing authorisation pursuant to Article 21a/22a/ 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

The application for Atropin Abboxia, 0,5 mg/ml and 1 mg/ml, solution for injection, is a generic application submitted according to Article 10(1) for 0,5 mg/ml and a hybrid application submitted according to Article 10(3) for 1 mg/ml of Directive 2001/83/EC.

The applicant, Abboxia AB applies for a marketing authorisation in Sweden through the Swedish National Procedure.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Atropin Mylan, 0,5 mg/ml, solution for injection authorised in SE since 1975, with Mylan AB as marketing authorisation holder.

Potential similarity with orphan medicinal products

According to the application form and a check of the Community Register of orphan medicinal products there is no medicinal product designated as an orphan medicinal product for a condition relating to the indication proposed in this application.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

Pharmacodynamic, pharmacokinetic and toxicological properties of active substance are well known. As active substance is a widely used, well-known active substance, no further studies are required, and the applicant provides none. Overview based on literature review is thus appropriate.

Environmental Risk Assessment (ERA)

Since Atropin Abboxia is a generic product, it will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary. However, an ERA has been submitted where a PEC_{sw} of 0,005 µg/ml is calculated, which is well below the action limit of 0,01 µg/L. This is agreed.

Abboxia certifies that Genetically Modified Organisms (GMO) are not used in the manufacture of the medicinal product. Therefore, this medicinal product is exempted from the possible risk to the environment and human health connected with the release of GMOs or products containing GMOs. This is accepted.

There are no objections to approval of product name from a non-clinical point of view.

IV. CLINICAL ASPECTS

Pharmacokinetics

Biowaiver

No bioequivalence study has been submitted. The applicant claims that a bioequivalence study is not necessary according to the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1) since the product is an aqueous parenteral solution.

0.5 mg/ml strength: The applied product is to be administered as an aqueous intravenous or subcutaneous solution containing the same active substance in the same concentration as the currently authorised product. The applied product also contains comparable excipients in similar amounts as the reference product. The reference product contains sodium chloride, hydrochloric acid and water for injection, while the applied product contains sulphuric acid instead of hydrochloric acid for pH adjustment. None of the excipients are known to interact with the drug substance and the difference in pH adjuster is not expected to affect the viscosity. For this type of product, no bioequivalence studies are required according to the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1).

1 mg/ml strength: The 1 mg/ml is a new strength and is to be administered as an aqueous intravenous solution containing the same active substance as the currently authorised product. For this type of product, no bioequivalence studies are required according to the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1).

Pharmacodynamics/Clinical efficacy/Clinical safety

No new studies on pharmacodynamics, clinical efficacy or clinical safety have been submitted. Provided that bioequivalence with the originator product is demonstrated, additional data is not necessary.

Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Atropin Abboxia.

Safety specification

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

Pharmacovigilance Plan

Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Risk minimisation measures

Routine risk minimisation is suggested and no additional risk minimisation activities are proposed by the applicant, which is endorsed.

Summary of the RMP

The submitted Risk Management Plan, version 0.1 signed 16 Febr 2021 is considered acceptable.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the MPA;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the PL was Swedish. The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the generic/hybrid product, Atropin Abboxia is found adequate. There are no objections to approval of Atropin Abboxia from a non-clinical and clinical point of view. The product information is acceptable.

The benefit risk balance for this product is considered positive, and the application for Atropin Abboxia, 0,5 mg/ml and 1 mg/ml, solution for injection is therefore recommended for approval.

List of recommendations not falling under Article 21a/22a/22 of Directive 2001/83/EC in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a/22a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

Atropin Abboxia, 0,5 mg/ml, 1 mg/ml, Solution for injection was approved in the national procedure on 2022-02-04.

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected (Yes/No)	Date of end of procedure	Approval/non approval	Summary/Justification for refuse
SE/H/2460/01-02/MR	Initial Mutual Recognition Procedure	Yes	2023-11-28	Approval	N/A

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)